Dyax Corporation (DYAX)
Q2 2012 Earnings Call
July 19, 2012, 5:00 p.m. ET
Gustav Christiansen – President, CEO
Rick Berard – VP Commercial
Burt Adelman – Chief Medical Officer
Ivana Magovčević-Liebisch - EVP, Corporate Development and General Counsel
George Miguasky - EVP, CFO.
Joseph Schwartz – Leerink Swann LLC
Phil Nadeau - Cowen and Company
Serge Boulanger – Needham and Company
Good afternoon, and welcome ladies and gentlemen to the Dyax Corporation Second Quarter 2012 financial earnings call. At this time, I would like to inform you that this conference call is being recorded, and that the participants are in a listen-only mode. (operator instructions).
Before turning this call over to Gustav Christiansen, President and Chief Executive Officer of Dyax, the company will now read their Safe Harbor Statement.
Unidentified Company Representative
This afternoon, Dyax issued a press release concerning second quarter 2012 financial results. Dyax would like to remind everyone that statements made today reflect current expectations, estimates and projections about products, programs, collaborations, strategies and financial performance, and are forward-looking statements. These statements, including those related to Dyax’s FDA-approved product KALBITOR, are subject to risks and uncertainties that could cause actual events and results to differ materially. Important information concerning these risks and uncertainties is contained in Dyax’s press release today, and described or referred to in its most recent form 10-K and other periodic reports filed with the SEC, and are also available on the company’s website at
. I will now turn the call over to Gustav Christiansen, President and CEO of Dyax. Gustav?